<DOC>
	<DOCNO>NCT00509899</DOCNO>
	<brief_summary>To determine safety , tolerability effectiveness ruxolitinib ( INCB018424 ) , administer orally patient Primary Myelofibrosis ( PMF ) , Post Polycythemia Vera Myelofibrosis ( PPV-MF ) Essential Thrombocythemia Myelofibrosis ( PET-MF ) .</brief_summary>
	<brief_title>Open Label Ruxolitinib ( INCB018424 ) Patients With Myelofibrosis Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis</brief_title>
	<detailed_description>This multicenter , open-label , non-randomized , dose escalation study ruxolitinib , small molecule Janus kinase ( JAK ) inhibitor , administer orally patient PMF , PPEV-MF PET-MF . The study comprise 3 part : Part 1 : Dose escalation determination maximum tolerate dose ( complete ) . Part 2 : Exploration alternative dosing schedule ( complete ) . Part 3 : Further evaluation select dose regimen , include additional response measure explore effect ruxolitinib symptom parameter include daily physical activity long-term survival ( ongoing ) .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Diagnosed PMF PostPV/ET MF Patients myelofibrosis require therapy Adequate bone marrow reserve Received anticancer medication investigational therapy past 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>